Literature DB >> 1657443

Species differences in myocardial beta-adrenergic receptor regulation in response to hyperthyroidism.

B Crozatier1, J B Su, A Corsin.   

Abstract

The coupling between myocardial beta-adrenergic receptors, adenylate cyclase activity, and the in vivo cardiac response to catecholamines is controversial in hyperthyroidism. The possibility of species differences in beta-adrenoceptor regulation after thyroxine treatment was studied in dogs and in rats. In dogs instrumented with a left ventricular (LV) pressure micromanometer, hyperthyroidism was induced by L-thyroxine (0.5 mg/kg/day i.v. for 10 days). After hyperthyroidism, heart rate was increased to 167 +/- 10 beats/min (control, 107 +/- 8 beats/min; p less than 0.005) with an increase of peak LV dP/dt from 4,243 +/- 471 to 6,105 +/- 862 mm Hg/sec (p less than 0.01). LV response to injection of increasing doses of isoproterenol and dobutamine was not significantly different before and after induction of the hyperthyroid state, as shown by the unchanged slopes of the LV peak dP/dt versus the log of the dose of isoproterenol and dobutamine. Bmax of beta-receptors measured in crude membranes using 3H-CGP 12177 and in homogenates using 125I-cyanopindolol was not increased in hyperthyroid animals as compared with a control group. Basal adenylate cyclase activity was not different in control and hyperthyroid dogs (32 +/- 3 versus 29 +/- 3 pmol/mg/min), and maximal adenylate cyclase activity response to isoproterenol was similar in control and hyperthyroid dogs. In contrast, in rats subjected to hyperthyroidism (0.5 mg/kg/day i.p. L-thyroxine for 10 days), Bmax of adrenoceptors measured using the same methods was significantly increased as compared with control (+72.5% using 3H-CGP 12177 and +41% using 125I-cyanopindolol, but adenylate cyclase activity was not increased in hyperthyroid rats. We conclude that both adenylate cyclase activity and LV response to catecholamines are not increased by thyroxine-induced hyperthyroidism in dogs and that, in contrast with rats, beta-adrenergic density is not increased in hyperthyroid dogs. This indicates a species difference in myocardial beta-adrenoceptor regulation in response to hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657443     DOI: 10.1161/01.res.69.5.1234

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

1.  No good deed goes unpunished!

Authors:  Alfred Ayala; Doreen E Wesche-Soldato; Megan Garber; Ryan Swan; Mario Perl
Journal:  Intensive Care Med       Date:  2006-04-01       Impact factor: 17.440

Review 2.  To scale or not to scale: the principles of dose extrapolation.

Authors:  Vijay Sharma; John H McNeill
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

3.  Beta adrenergic and muscarinic receptors in compensatory cardiac hypertrophy of the adult rat.

Authors:  P Mansier; B Chevalier; D B Barnett; B Swynghedauw
Journal:  Pflugers Arch       Date:  1993-08       Impact factor: 3.657

Review 4.  Takotsubo cardiomyopathy associated with thyrotoxicosis: a case report and review of the literature.

Authors:  Myrto Eliades; Diala El-Maouche; Chitra Choudhary; Bruce Zinsmeister; Kenneth D Burman
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

5.  Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C.

Authors:  Carmen Sorina Martin; Luminita Nicoleta Ionescu; Carmen Gabriela Barbu; Anca Elena Sirbu; Ioana Maria Lambrescu; Ioana Smarandita Lacau; Doina Ruxandra Dimulescu; Simona Vasilica Fica
Journal:  BMC Endocr Disord       Date:  2014-02-03       Impact factor: 2.763

Review 6.  Association of Endocrine Conditions With Takotsubo Cardiomyopathy: A Comprehensive Review.

Authors:  Sonali Gupta; Pradeep Goyal; Sana Idrees; Sourabh Aggarwal; Divyansh Bajaj; Joseph Mattana
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.